Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.47 |
| ▸ | GBA1 | P04062 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455276 | 0.92 | AKT1 (0.48) | AKT1GBA1ALDH1A1KDM4EMAPT | |
| SCHEMBL31455115 | 0.92 | AKT1 (0.48) | AKT1GBA1ALDH1A1KDM4EMAPT | |
| SCHEMBL31455571 | 0.90 | AKT1 (0.47) | AKT1GBA1AKT2AKT3 | |
| SCHEMBL31455280 | 0.86 | AKT1 (0.48) | AKT1AKT2AKT3 | |
| SCHEMBL31455458 | 0.83 | AKT1 (0.49) | AKT1MAPTAKT2AKT3 | |
| SCHEMBL31455404 | 0.81 | AKT1 (0.48) | AKT1GBA1AKT2AKT3 | |
| SCHEMBL31455520 | 0.81 | AKT1 (0.48) | AKT1GBA1AKT2AKT3 | |
| SCHEMBL31455230 | 0.79 | AKT1 (0.56) | AKT1MAPTAKT2AKT3 | |
| SCHEMBL31455097 | 0.78 | AKT1 (0.55) | AKT1AKT2AKT3 | |
| SCHEMBL31455284 | 0.78 | AKT1 (0.49) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |